SII to apply for Oxford COVID-19 vaccine trials in India in a week
New Delhi: The Serum Institute of India (SII) will soon apply to the Indian regulator for the licensure trials of the AstraZeneca-Oxford COVID-19 vaccine.
Commenting on the AstraZeneca-Oxford vaccine’s results, Adar Poonawalla, CEO, Serum Institute of India, said, “The trials have shown promising results and we are extremely happy about it. We will be applying for the licensure trials to the Indian regulator in a week’s time. As soon as they grant us permission, we will begin with trials for the vaccine in India. In addition, we will soon start manufacturing the vaccine in large volumes.”
Monday marked an important day in the battle against COVID as the first results of Oxford’s Covid-19 vaccine showed that it is safe and provokes an immune reaction in a person that lasts for almost two months.
The researchers are indicating that the vaccine may be ready by year-end. The results showed that more than 91 per cent of volunteers injected produced an immune response against coronavirus which lasted for a month or more. The immune responses remained strong for at least 56 days.
Oxford University’s vaccine, called AZD1222, is being manufactured by pharmaceutical major AstraZeneca and the UK government has ordered 100 million doses ahead of time.
As per the results, the vaccine boosted T cell and antibody immunity. The vaccine produced strong responses on both accounts, the study found, with T cell immunity peaking after two weeks and then dropping slightly by day 56.
Antibody immunity, on the other hand, peaked after four weeks and remained high by day 56, indicating that it may well last for even longer.